ESMO 2018 Congress
A study presented at ESMO 2018 demonstrated that incidence of skin toxicity in patients with multiple myeloma undergoing lenalidomide therapy was lower in those who received prior bortezomib.
Assessment of a subgroup of a cohort study revealed that many patients undergoing tamoxifen therapy for early-stage breast cancer do not adhere to their prescribed treatment, even though they claim adherence on patient surveys.
An analysis of pooled data from 4 randomized controlled clinical trials revealed that male and female patients experience different chemotherapy side effects and at different severities, according to a poster presented at ESMO 2018 Congress.
Researchers surveyed 60 breast cancer survivors to determine if their desire to achieve pregnancy had changed after completing treatment. These findings were presented at ESMO 2018 Congress.
Study findings presented at ESMO 2018 Congress revealed the effect of a shorter, 9-week course of trastuzumab on disease-free survival (DFS) and cardiac toxicity in women with HER2-positive breast cancer.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Medication, Vaccination Uptake Improved by Involving Pharmacists in Elder Cancer Care
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Molecular Features May Predict Response in Primary Pancreatic Cancer
- Commission Seeks Standardized Adverse Event Assessments in Hematologic Malignancies
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Clinical Characteristics That Increase Risk of Chemotherapy-Induced Febrile Neutropenia Identified
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Counseling Patients on Oral Chemotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|